Stryker (NYSE:SYK) Stock Lifted to “Strong-Buy” by Barclays

Barclays upgraded shares of Stryker (NYSE:SYK) to a strong-buy rating in a research note published on Wednesday,Zacks reports.

A number of other equities analysts have also commented on SYK. Citizens Jmp decreased their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a report on Monday, August 3rd. TD Cowen dropped their price objective on shares of Stryker from $355.00 to $298.00 and set a “hold” rating for the company in a report on Tuesday, September 22nd. Wells Fargo & Company cut their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research report on Wednesday, September 9th. Truist Financial reduced their target price on Stryker from $340.00 to $310.00 and set a “hold” rating on the stock in a research note on Tuesday. Finally, JPMorgan Chase & Co. lowered their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $370.68.

Stryker Price Performance

Shares of NYSE SYK opened at $275.17 on Wednesday. The stock’s 50-day simple moving average is $306.83 and its two-hundred day simple moving average is $315.02. Stryker has a twelve month low of $267.00 and a twelve month high of $392.55. The firm has a market capitalization of $105.55 billion, a P/E ratio of 28.51, a P/E/G ratio of 1.76 and a beta of 0.78. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts anticipate that Stryker will post 14.97 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.3%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the transaction, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 in the last 90 days. 4.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stryker

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Amundi raised its stake in Stryker by 18.3% during the 2nd quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock worth $392,402,000 after acquiring an additional 192,447 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Stryker by 8.2% in the second quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock worth $270,642,000 after purchasing an additional 65,333 shares during the period. Veritas Asset Management LLP bought a new position in shares of Stryker in the second quarter worth approximately $168,057,000. Bank of America Corp DE purchased a new stake in shares of Stryker in the second quarter worth $1,404,284,000. Finally, Rakuten Investment Management Inc. bought a new stake in shares of Stryker during the 2nd quarter valued at $18,646,000. 77.09% of the stock is currently owned by institutional investors.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Current President and COO Spencer Stiles will succeed Kevin Lobo as CEO on January 1, 2027, while Lobo becomes executive chair. The planned succession provides continuity because Stiles is an established internal leader familiar with Stryker’s operations and strategy. Stryker announces leadership succession
• Positive Sentiment: Needham said Stiles is a known entity to investors and well prepared to lead the company, supporting the view that the transition should not materially disrupt execution. Needham comments on Stiles
• Positive Sentiment: Truist also described the CEO change as low-risk, suggesting investor concerns may be manageable even though it reduced its price target to $310. Truist CEO transition commentary
• Neutral Sentiment: Coverage has focused on whether the leadership change will affect Stryker’s long-term growth and valuation relative to medical-device peers. A comparison with Boston Scientific noted that both stocks have weakened substantially, while Boston Scientific has higher margins. Stryker versus Boston Scientific
• Negative Sentiment: Investors initially reacted cautiously to the CEO announcement, likely reflecting uncertainty over replacing Lobo after his long tenure. The stock’s broader weakness and Truist’s lower price target reinforce near-term valuation concerns. Why Stryker dropped
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of Stryker investors. Such notices can add sentiment and headline risk, although the announcement does not establish wrongdoing. Pomerantz investor investigation

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker’s product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.